The	O
regulatory	O
domain	O
or	O
the	O
aminoteminus	O
of	O
the	O
PKCs	O
contains	O
several	O
shared	O
subregions	O
.	O
The	O
C1	O
domain	O
,	O
present	DATE
in	O
all	O
of	O
the	O
isoforms	O
of	O
PKC	ORGANIZATION
has	O
a	O
bindingsite	O
for	O
DAG	O
as	O
well	O
as	O
nonhydrolysable	O
,	O
nonphysiological	O
analogues	O
calledphorbol	O
esters	O
.	O
This	O
domain	O
is	O
functional	O
and	O
capable	O
of	O
binding	O
DAG	O
in	O
both	O
conventional	O
and	O
novel	O
isoforms	O
,	O
however	O
,	O
the	O
C1	O
domain	O
in	O
atypical	O
PKCs	O
isincapable	O
of	O
binding	O
to	O
DAG	O
or	O
phorbol	O
esters	O
.	O
The	O
C2	O
domain	O
acts	O
as	O
a	O
Ca2	O
+	O
sensor	O
and	O
is	O
present	DATE
in	O
both	O
conventional	O
and	O
novel	O
isoforms	O
,	O
but	O
functionalas	O
a	O
Ca2	O
+	O
sensor	O
only	O
in	O
the	O
conventional	O
.	O
The	O
pseudosubstrate	O
region	O
,	O
whichis	O
present	DATE
in	O
all	O
three	NUMBER
classes	O
of	O
PKC	ORGANIZATION
,	O
is	O
a	O
small	O
sequence	O
of	O
amino	O
acids	O
that	O
mimic	O
a	O
substrate	O
and	O
bind	O
the	O
substratebinding	O
cavity	O
in	O
the	O
catalyticdomain	O
,	O
lack	O
critical	O
serine	MEDICINE
,	O
threonine	O
phosphoacceptor	O
residues	O
,	O
keeping	O
theenzyme	O
inactive	O
.	O
When	O
Ca2	O
+	O
and	O
DAG	O
are	O
present	DATE
in	O
sufficient	O
concentrations	O
,	O
they	O
bind	O
to	O
the	O
C2	O
and	O
C1	O
domain	O
,	O
respectively	O
,	O
and	O
recruit	O
PKC	ORGANIZATION
to	O
themembrane	O
.	O
This	O
interaction	O
with	O
the	O
membrane	O
results	O
in	O
release	O
of	O
thepseudosubstrate	O
from	O
the	O
catalytic	O
site	O
and	O
activation	O
of	O
the	O
enzyme	MEDICINE
.	O
In	O
order	O
for	O
these	O
allosteric	O
interactions	O
to	O
occur	O
,	O
however	O
,	O
PKC	ORGANIZATION
must	O
first	ORDINAL
be	O
properly	O
folded	O
and	O
in	O
the	O
correct	O
conformation	O
permissive	O
for	O
catalyticaction	O
.	O
This	O
is	O
contingent	O
upon	O
phosphorylation	O
of	O
the	O
catalytic	O
region	O
,	O
discussed	O
below	O
.	O
